EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model‐Informed Dosing Recommendations for Anticancer Drugs

Theunis C Goosen iD, Xiaofeng Wu iD, Jian Lin, Narayan Cheruvu, Susan R Raber, Maria Lavinea Novis de Figueiredo, Manthena V S Varma iD

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.70123 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Theunis C Goosen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacokinetics, Dynamics and Metabolism, Pfizer Research and Development, Pfizer Inc, Groton, Connecticut, USA. Hauptthemen laut MEDLINE: Nitriles, Triazoles, Antifungal Agents, Pyridines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Isavuconazole is a broad‐spectrum triazole approved for the treatment of invasive aspergillosis or mucormycosis in adults and children aged ≥ 1 year. Current prescribing information lacks guidance regarding the co‐administration of isavuconazole with anticancer drugs–limited by the availability of clinical drug–drug interaction (DDI) data in the patient population. This study utilized physiologically‐based pharmacokinetic (PBPK) modeling to evaluate the DDI risk of isavuconazole compared with other azoles and provide dosing recommendations when co‐administered with anticancer drugs (ibrutinib, venetoclax, and midostaurin). PBPK models were developed in the Simcyp simulator using physiochemical properties, in vitro, and clinical pharmacokinetic data. The model well‐predicted isavuconazole pharmacokinetic changes with cytochrome‐P450 3A (CYP3A) modulators (itraconazole and rifampicin), and recovered midazolam DDI with isavuconazole as a CYP3A inhibitor. PBPK models for ibrutinib, venetoclax, and midostaurin were developed and validated by comparing simulated and observed pharmacokinetic parameters with and without the CYP3A inhibitor, ketoconazole. The PBPK model predicted area under the plasma concentration–time curve ratios of 2.1, 1.1, and 2.1 for ibrutinib, venetoclax, and midostaurin, respectively, when co‐administered with isavuconazole at clinically relevant doses. The findings suggest that isavuconazole can be safely co‐administered following appropriate dose adjustments with ibrutinib (50% of normal dose), venetoclax (50–100% of normal dose), or midostaurin (50% of normal dose). Other azoles, posaconazole and voriconazole, showed larger CYP3A‐mediated DDIs and consequently require 3–6‐fold lower doses of the substrate drugs. In conclusion, this model‐informed PK‐based dose optimization can enable treatment management in these untested scenarios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitrilesTriazolesAntifungal AgentsPyridinesModels, BiologicalAntineoplastic AgentsHumansDrug InteractionsCytochrome P-450 CYP3A InhibitorsSulfonamidesStaurosporineAdeninePyrimidinesAdultPiperidinesBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

CYP3Aazolesdosing recommendationsdrug–drug interactionsisavuconazolephysiologically‐based pharmacokinetic modeling

Substanzen

isavuconazoleNitrilesTriazolesAntifungal AgentsPyridinesAntineoplastic AgentsvenetoclaxCytochrome P-450 CYP3A InhibitorsSulfonamidesStaurosporine

Autor:innen und Institutionen

  • Pharmacokinetics, Dynamics and Metabolism, Pfizer Research and Development, Pfizer Inc, Groton, Connecticut, USA.
  • Pfizer Inc, Collegeville, Pennsylvania, USA.
  • Clinical Pharmacology, Pfizer Research and Development, Pfizer Inc, San Diego, California, USA.
  • Pfizer Inc, São Paulo, Brazil.

ORCID-Profile: Theunis C Goosen, Xiaofeng Wu, Manthena V S Varma

Zitieren

APA

Goosen, T. C., Wu, X., Lin, J., Cheruvu, N., Raber, S. R., de Figueiredo, M. L. N., & Varma, M. V. S. (2025). Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model‐Informed Dosing Recommendations for Anticancer Drugs. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70123

Vancouver

Goosen TC, Wu X, Lin J, Cheruvu N, Raber SR, de Figueiredo MLN, et al. Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model‐Informed Dosing Recommendations for Anticancer Drugs. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70123

BibTeX
@article{Goosen2025,
  author = {Goosen, Theunis C and Wu, Xiaofeng and Lin, Jian and Cheruvu, Narayan and Raber, Susan R and de Figueiredo, Maria Lavinea Novis and Varma, Manthena V S},
  title = {Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model‐Informed Dosing Recommendations for Anticancer Drugs},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.70123}
}
Kostenlos starten →